GB:0GZK Stock Latest News
Company AnnouncementsIBA Wins German Contract for Next-Generation Electron Beam Sterilization Facility1w ago
Company AnnouncementsIBA Marks First Patient Treated in ConformalFLASH Proton Therapy Trial1w ago
Company AnnouncementsIBA and ORA launch NEPTIS Perform Duo to streamline radiopharmaceutical tracer production1w ago
Company AnnouncementsIBA and Framatome launch Ekalia JV to scale Astatine-211 cancer therapies2w ago
Company AnnouncementsIBA wins major U.S. contract to build national PET radiopharmaceutical network2w ago
Company AnnouncementsIBA Discloses Vallcara’s Stake Crossing 7.5% Ownership Threshold1M agoCompany AnnouncementsIBA to Distribute ARTMS Solid-Target Technology to Scale Radiometal Production1M ago
Company AnnouncementsIBA Wins Contract for First Rotating-Gantry Proton Therapy System in Central-Southern Italy1M ago
Company AnnouncementsPenn Medicine and IBA Launch Noventra Alliance to Guide Proton Therapy Expansion1M ago
Company AnnouncementsIBA launches integrated QUASAR Penta-Guide QA phantom for advanced radiotherapy1M ago
Company AnnouncementsIBA to Lead EU-Backed PFAS Remediation Project Using Accelerator Technology1M ago
Company AnnouncementsIBA Reports Axxion Stake Falls Below 1% Threshold Under Belgian Transparency Law1M ago
Company AnnouncementsIBA Joins EU PFAROS Initiative to Develop PFAS Destruction Technologies for Healthcare Waste2M agoCompany AnnouncementsIBA posts stronger H1 2026 profit, reiterates guidance amid proton therapy surge2M ago
Company AnnouncementsIBA Launches Wireless QA System for Next-Generation Particle Therapy7M ago
Company AnnouncementsIBA Announces Transparency Notification as Axxion S.A. Stake Rises Above 1%9M ago
Company AnnouncementsIon Beam Applications’ PROTEUS® PLUS Trial: A Potential Game-Changer in Proton Therapy1y ago0GZK
Company AnnouncementsIon Beam Applications’ PROTEUS® PLUS Trial: A Step Forward in Proton Therapy1y ago0GZK
Company AnnouncementsIon Beam Applications SA Advances with PROTEUS® PLUS Clinical Trial1y ago0GZK
